NCT07625202

Brief Summary

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
19mo left

Started May 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
May 2026Dec 2027

First Submitted

Initial submission to the registry

May 25, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

May 25, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 4, 2026

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2027

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 4, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

May 25, 2026

Last Update Submit

May 30, 2026

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (1)

  • Change in sit to stand performance (number of times)

    change in number of times sitting and standing in 30 seconds

    12 weeks

Secondary Outcomes (16)

  • Change in 10 meter gait speed (m/s)

    12 weeks

  • Change in timed up and go (m/s)

    12 weeks

  • Change in lean tissue mass (kg)

    12 weeks

  • Change in fat mass (kg)

    12 weeks

  • Change in whole body bone mineral density (g/cm squared)

    12 weeks

  • +11 more secondary outcomes

Study Arms (2)

Creatine

EXPERIMENTAL

10 grams per day creatine

Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (creatine)

Placebo

PLACEBO COMPARATOR

Placebo (maltodextrin)

Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (placebo)

Interventions

Dietary supplementation during a 12 week resistance-training program (creatine)DIETARY_SUPPLEMENT

creatine supplementation

Creatine
Dietary supplementation during a 12 week resistance-training program (placebo)DIETARY_SUPPLEMENT

Placebo

Placebo

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Gender Eligibility DetailsAll genders are eligible
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Starting GLP-1 agonist therapy
  • years of age or older

You may not qualify if:

  • Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Saskatchewan

Saskatoon, SK - Saskatchewan, S7N 5B2, Canada

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Interventions

Creatine

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

GuanidinesAmidinesOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Philip Chilibeck, PhD

    University of Saskatchewan

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Philip D Chilibeck, PhD

CONTACT

306-966-1072phil.chilibeck@usask.ca

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 25, 2026

First Posted

June 4, 2026

Study Start

May 25, 2026

Primary Completion (Estimated)

May 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

June 4, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations

CA(1)